Overview

Ecopipam Tablets to Study Tourette's Disorder in Children and Adolescents

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
Phase:
Phase 3
Details
Lead Sponsor:
Emalex Biosciences Inc.
Treatments:
Ecopipam